山东科学 ›› 2020, Vol. 33 ›› Issue (2): 1-11.doi: 10.3976/j.issn.1002-4026.2020.02.001
• 新冠肺炎防控 • 下一篇
孙晨1a,1b,何秋霞1a,1b,高燕1a,1b,张磊2,李宁1a,1b,刘可春1a,1b*
收稿日期:
2020-02-25
出版日期:
2020-04-20
发布日期:
2020-03-30
通信作者:
刘可春(1964—),男,博士,研究员,研究方向为药物筛选。Tel: 15020009568
E-mail:hliukch@sdas.org
作者简介:
孙晨(1985—),女,博士,助理研究员,研究方向为药物筛选。E-mail: mornings0123@163.com
何秋霞(1980—),共同第一作者,女,博士,副研究员,研究方向为药物筛选。E-mail: heqiuxia8008@163.com
基金资助:
SUN Chen1a,1b, HE Qiu-xia1a,1b, GAO Yan1a,1b, ZHANG Lei2, LI Ning1a,1b, LIU Ke-chun1a,1b*
Received:
2020-02-25
Online:
2020-04-20
Published:
2020-03-30
摘要: 新冠肺炎的爆发严重危害人类健康和公共卫生安全,已引起全球范围内的高度关注。预防病毒性疾病最有效的措施是接种疫苗,但是目前还没有专门针对新型冠状病毒的疫苗。考虑到疫情的严重性,对同为RNA病毒的流感病毒、其他冠状病毒相关疫苗的研究进行了综述,并通过对这些病毒氨基酸水平的序列比对发现,新冠病毒的棘突糖蛋白与H1N1、H3N2、B型Victoria系和B型Yamagata系流感病毒的血凝素糖蛋白之间具有一定的相似性。由于血凝素糖蛋白是目前商用流感疫苗的主要作用靶点,因此推测,现有季节性商用流感疫苗在新冠肺炎的防控方面可能也具有一定的应用潜能。除此之外,由于新冠病毒与SARS冠状病毒的棘突糖蛋白和核蛋白之间均具有高度的相似性,而SARS冠状病毒疫苗又主要从上述两种蛋白研制而来,因此建议在短期内,可以将目前正在研制的SARS冠状病毒疫苗作为新冠病毒特效疫苗的替代物来使用。
中图分类号:
孙晨, 何秋霞, 高燕, 张磊, 李宁, 刘可春. 现有病毒疫苗用于防治新冠肺炎的可行性分析[J]. 山东科学, 2020, 33(2): 1-11.
SUN Chen, HE Qiu-xia, GAO Yan, ZHANG Lei, LI Ning, LIU Ke-chun. Exploring preventive measures for COVID-19 based on the existing virus vaccines[J]. Shandong Science, 2020, 33(2): 1-11.
1 |
CHEN N S, ZHOU M, DONG X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. The Lancet, 2020, 395(10223): 507-513.
doi: 10.1016/S0140-6736(20)30211-7 |
2 | 中国新闻网. 黑龙江省3例新冠肺炎死亡患者均为患有慢性疾病老年人[EB/OL]. (2020-02-09)[2020-02-25].http://www.chinanews.com/sh/2020/02-09/9084552. |
3 | 国家卫生健康委员会. 截至2月24日24时新型冠状病毒肺炎疫情最新情况[EB/OL]. (2020-02-25)[2020-02-25].http://www.nhc.gov.cn/xcs/yqtb/202002/67e6c59a84bd4f07b6ca4a4c5ffabb79.shtml. |
4 | 国家卫生健康委办公厅. 新型冠状病毒肺炎诊断方案(试行第六版)[EB/OL]. (2020-02-19)[2020-02-25].http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdf. |
5 | 北青网. 新冠肺炎康复者血浆治疗超10人临床症状明显好转[EB/OL]. (2020-02-14)[2020-02-25].https://www.xianjichina.com/news/details_185590.html. |
6 |
PALESE P. Influenza: old and new threats[J]. Nature Medicine, 2004, 10(12): 82-87.
doi: 10.1038/nm1141 |
7 |
IULIANO A D , ROGUSKI K M , CHANG H H , et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study[J]. The Lancet, 2017, 391(10127): 1285-1300. DOI:10.1016/S0140-6736(17)33293-2.
doi: 10.1016/S0140-6736(17)33293-2 |
8 |
TRUCCHI C, PAGANINO C, AMICIZIA D, et al. Universal influenza virus vaccines: what needs to happen next[J]. Expert Opinion on Biological Therapy, 2019, 19(7): 671-683.
doi: 10.1080/14712598.2019.1604671 |
9 | 高福, 施一. 中国流感病毒结构生物学研究:40年回眸[J]. 生物化学与生物物理进展, 2014(10): 1029-1033. |
10 |
DU L Y, ZHOU Y S, JIANG S B. Research and development of universal influenza vaccines[J]. Microbes and Infection, 2010, 12(4): 280-286.
doi: 10.1016/j.micinf.2010.01.001 |
11 |
FOUCHIER R A M, MUNSTER V, WALLENSTEN A, et al. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls[J]. Journal of Virology, 2005, 79(5): 814-2822.
doi: 10.1128/jvi.79.5.2814-2822.2005 |
12 |
SKEHEL J J, WILEY D C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin[J]. Annual Review of Biochemistry, 2000, 69(1): 531-569.
doi: 10.1146/annurev.biochem.69.1.531 |
13 |
FONI E, CHIAPPONI C, BAIONI L, et al. Influenza D in Italy: towards a better understanding of an emerging viral infection in swine[J]. Scientific Reports, 2017, 7(1): 11660.
doi: 10.1038/s41598-017-12012-3 |
14 | 中国疾病预防控制中心. 中国流感疫苗预防接种技术指南(2019—2020)[EB/OL].(2019-10-16)[2020-02-25].http://www.chinacdc.cn/jkzt/crb/bl/lxxgm/jszl_2251/201910/t20191016_206297.html. |
15 |
HANNOUN C. The evolving history of influenza viruses and influenza vaccines[J]. Expert Review of Vaccines, 2013, 12(9): 1085-1094.
doi: 10.1586/14760584.2013.824709 |
16 |
BERLANDA SCORZA F, TSVETNITSKY V, DONNELLY J J. Universal influenza vaccines: shifting to better vaccines[J]. Vaccine, 2016, 34(26): 2926-2933.
doi: 10.1016/j.vaccine.2016.03.085 |
17 |
AMBROSE C S, LEVIN M J. The rationale for quadrivalent influenza vaccines[J]. Human Vaccines & Immunotherapeutics, 2012, 8(1): 81-88.
doi: 10.4161/hv.8.1.17623 |
18 |
JAZAYERI S D, POH C L. Development of universal influenza vaccines targeting conserved viral proteins[J]. Vaccines, 2019, 7(4): 169.
doi: 10.3390/vaccines7040169 |
19 |
KUBO H, YAMADA Y K, TAGUCHI F. Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein[J]. Journal of Virology, 1994, 68(9): 5403-5410.
doi: 10.1128/jvi.68.9.5403-5410.1994 |
20 |
MCBRIDE R, VAN ZYL M, FIELDING B. The coronavirus nucleocapsid is a multifunctional protein[J]. Viruses, 2014, 6(8): 2991-3018.
doi: 10.3390/v6082991 |
21 |
HAMRE D, PROCKNOW J J. A new virus isolated from the human respiratory tract[J]. Experimental Biology and Medicine, 1966, 121(1): 190-193.
doi: 10.3181/00379727-121-30734 |
22 |
HENDLEY J O, FISHBURNE H B,Jr GWALTNEY J M. Coronavirus infections in working adults eight-year study with 229 E and OC 43[J]. The American Review of Respiratory Disease, 1972, 105(5): 805-811.
doi: 10.1164/arrd.1972.105.5.805 |
23 |
der VAN H L, PYRC K, JEBBINK M F, et al. Identification of a new human coronavirus[J]. Nature Medicine, 2004, 10(4): 368-373.
doi: 10.1038/nm1024 |
24 |
FRIEDMAN N, ALTER H, HINDIYEH M, et al. Human coronavirus infections in Israel: epidemiology, clinical symptoms and summer seasonality of HCoV-HKU[J]. Viruses, 2018, 10(10): 515.
doi: 10.3390/v10100515 |
25 |
孟娟丽, 沈晓玲, 谭文杰. SARS冠状病毒病毒样颗粒疫苗的研究进展[J]. 生物技术通讯, 2014,25(2): 268-271.
doi: 10.3969/j.issn.1009-0002.2014.02.027 |
26 |
B-EZ-SANTOS Y M, ST J S E, MESECAR A D. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds[J]. Antiviral Research, 2015, 115: 21-38.
doi: 10.1016/j.antiviral.2014.12.015 |
27 |
LUIS E, MARTA LDD, ENRIQUE A, et al. Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease[J]. Virus Research, 2008, 133(1): 45-62.
doi: 10.1016/j.virusres.2007.01.021 |
28 |
广东省防治非典型肺炎科技攻关疫苗专题组.SARS 冠状病毒灭活疫苗研究初报[J].广东医学,2003,24(增刊1):129-130. DOI:10.13820/j.cnki.gdyx.2003.s1.051.
doi: 10.13820/j.cnki.gdyx.2003.s1.051 |
29 |
曾玉红. SARS 疫苗研究进展[J]. 国际免疫学杂志,2007, 30( 4) : 266-269.
doi: 10.3760/cma.j.issn.1673-4394.2007.04.018 |
30 |
MARSHALL E, ENSERINK M. Medicine. Cautionurged on SARS vaccines[J]. Science, 2004, 303(5660): 944-946.
doi: 10.1126/science.303.5660.944 |
31 |
RACHEL L G, ERIC F D, RALPH S B. A decade after SARS: strategies for controlling emerging coronaviruses[J]. Nature Reviews Microbiology, 2013, 11(12): 836-848.
doi: 10.1038/nrmicro3143 |
32 |
LI F, LI W, FARZAN M et al. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor[J]. Science, 2005, 309(5742): 1864-1868.
doi: 10.1126/science.1116480 |
33 |
GUPTA V, TABIIN T M, SUN K, et al. SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens[J]. Virology, 2006, 347(1): 127-139.
doi: 10.1016/j.virol.2005.11.042 |
34 |
FETT C, DEDIEGO M L, REGLANAVA J A, et al. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein[J]. Journal of Virology, 2013, 87(12): 6551-6559.
doi: 10.1128/JVI.00087-13 |
35 |
GRAHAM R L, BECKER M M, ECKERLE L D, et al. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease[J]. Nature Medicine, 2012, 18(12): 1820-1826.
doi: 10.1038/nm.2972 |
36 |
BISHT H, ROBERTS A, VOGEL L, et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice[J]. Proceedings of the National Academy of Sciences, 2004, 101(17): 6641-6646.
doi: 10.1073/pnas.0401939101 |
37 |
BUCHHOLZ U J, BUKREYEV A, YANG L, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity[J]. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101(26): 9804-9809.
doi: 10.1073/pnas.0403492101 |
38 |
FABER M, LAMIRANDE E W, ROBERTS A, et al. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies[J]. Journal of General Virology, 2005, 86(5): 1435-1440.
doi: 10.1099/vir.0.80844-0 |
39 |
KAPADIA S U, ROSE J K, LAMIRANDE E, et al. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine[J]. Virology, 2005, 340(2): 174-182.
doi: 10.1016/j.virol.2005.06.016 |
40 |
LIU S J, LENG C H, LIEN S P, et al. Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates[J]. Vaccine, 2006, 24(16): 3100-3108.
doi: 10.1016/j.vaccine.2006.01.058 |
41 |
CHEN Z, ZHANG L, QIN C, et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region[J]. Journal of Virology, 2005, 79(5): 2678-2688.
doi: 10.1128/JVI.79.5.2678-2688.2005 |
42 |
WOO P C Y, LAU S K P, TSOIH W , et al. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus[J]. Vaccine, 2005, 23(42): 4959-4968.
doi: 10.1016/j.vaccine.2005.05.023 |
43 |
SHI S Q, PENG J P, LI Y C, et al. The of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization[J]. Molecular Immunology, 2006, 43(11): 1791-1798.
doi: 10.1016/j.molimm.2005.11.005 |
44 |
HUI D S, AZHAR E I, KIM Y J, et al. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission[J]. The Lancet Infectious Diseases, 2018, 18(8): e217-e227.
doi: 10.1016/S1473-3099(18)30127-0 |
45 | World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV)[EB/OL].[2020-02-25].https://www.who.int/emergencies/mers-cov/en/. |
46 |
CHAFEKAR A, FIELDING B C. MERS-CoV: understanding the latest human coronavirus threat[J]. Viruses, 2018, 10(2): E93. DOI:10.3390/v10020093.
doi: 10.3390/v10020093 |
47 |
ZHOU Y S,JIANG S B,DU L Y.Prospects for a MERS-CoV spike vaccine[J].Expert Review of Vaccines, 2018, 17(8): 677-686.
doi: 10.1080/14760584.2018.1506702 |
48 |
LEE J Y, BAE S, MYOUNG J. Middle East respiratory syndrome coronavirus-encoded ORF8b strongly antagonizes IFN-β promoter activation: its implication for vaccine design[J]. Journal of Microbiology, 2019, 57(9): 803-811.
doi: 10.1007/s12275-019-9272-7 |
49 |
CHAN J W, KOK K H, ZHU Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan[J]. Emerging Microbes Infections, 2020, 9(1): 221-236.
doi: 10.1080/22221751.2020.1719902 |
50 |
CERAOLO C, GIORGI F M. Genomic variance of the 2019-nCoV coronavirus[EB/OL]. (2020-02-06)[2020-02-25].https://doi.org/10.1002/jmv.25700.
doi: doi.org/10.1002/jmv.25700 |
51 |
BENVENUTO D, GIOVANNETTI M, CICCOZZI A, et al. The 2019-new coronavirus epidemic: Evidence for virus evolution[EB/OL].(2020-01-29)[2020-02-25].https://doi.org/10.1002/jmv.25688.
doi: 10.1002/jmv.25688 |
52 |
WRAPP D, WANG N, CORBETT K S, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[EB/OL]. (2020-02-15)[2020-02-25]. https://doi.org/ 10.1126/science.abb2507.
doi: 10.1126/science.abb2507 |
53 | 陈晶, 金焱, 马可欣. 非典时期我们没有用上疫苗,这次能吗?[EB/OL]. (2020-02-11)[2020-02-25]. https://xw.qq.com/cmsid/20200210A0PSHN00. |
54 | 医诺医学. 好消息!Vir 鉴定出两种可与新冠肺炎病毒结合的单克隆抗体[EB/OL]. (2020-02-13)[2020-02-25]. http://www.ulabmed.com/content-154-5248-1.html. |
55 | 医麦客. 新冠疫苗:Moderna完成临床级产品的生产分装,即将投入临床 [EB/OL]. (2020-02-12)[2020-02-25]. https://xueqiu.com/5603603160/141073949. |
56 |
周烨真, 张世豪, 陈嘉仪, 等.新型冠状病毒SARS-CoV-2的变异和进化分析J . 南方医科大学学报,2020,40(2): 152-158.
doi: 10.12122/j.issn.1673-4254.2020.02.02 |
[1] | 朱洁, 王征, 梁艳妮. 基于网络药理学探究小青龙汤治疗新型冠状病毒肺炎的作用机制[J]. 山东科学, 2023, 36(3): 10-17. |
[2] | 杜海涛, 王平, 李娜, 丁洁, 张敬, 袁成民, 孙铁锋, 韩莉, 张忠法. 基于网络药理学与分子对接的新冠肺炎三焦疫毒寒湿症用药机理研究 [J]. 山东科学, 2021, 34(1): 1-9. |
[3] | 刘京华, 谭旺晓, 王斯维, 王雨, 王小莹. 基于网络药理学探讨葶苈大枣泻肺汤治疗新冠肺炎的作用机制[J]. 山东科学, 2020, 33(5): 1-13. |
[4] | 汪宗清, 聂红科, 李青璇, 王兴强, 汤小虎. 基于网络药理学探讨黄芪六君子汤治疗新冠肺炎恢复期的作用机制[J]. 山东科学, 2020, 33(5): 14-26. |
[5] | 孙慧囡, 高广恒, 刘庆艾, 马耀宏, 李静, 史建国. 血乳酸生物传感器在新冠肺炎诊疗中的应用探讨[J]. 山东科学, 2020, 33(3): 1-6. |
[6] | 孙强, 边昕. 基于太阳光紫外线和风环境模拟的武汉雷神山医院防疫工作规划分析响应[J]. 山东科学, 2020, 33(3): 7-17. |
[7] | 徐瑞东, 田明伟. 一次性医用防护服研究进展[J]. 山东科学, 2020, 33(3): 18-27. |
[8] | 王凤霞, 张云, 刘可春. 基于《伤寒论》理法方药理论浅谈新冠肺炎防控策略[J]. 山东科学, 2020, 33(2): 12-16. |
[9] | 牛凌, 景元旺, 罗磷. 智慧化交通在疫情联防联控中的应用探讨[J]. 山东科学, 2020, 33(2): 17-21. |
|